Comparison 1. Ranolazine (monotherapy) 1000 mg twice daily versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Cardiovascular mortality	1	2604	Risk Ratio (M‐H, Fixed, 95% CI)	1.03 [0.56, 1.88]
2 All‐cause mortality	3	6249	Risk Ratio (M‐H, Fixed, 95% CI)	1.00 [0.81, 1.25]
3 Quality of life	3	2254	Mean Difference (IV, Fixed, 95% CI)	0.28 [‐1.57, 2.13]
4 AMI incidence	2	2674	Risk Ratio (M‐H, Random, 95% CI)	0.55 [0.14, 2.15]
5 Need for revascularisation procedure	2	2674	Risk Ratio (M‐H, Fixed, 95% CI)	0.98 [0.82, 1.18]
6 Adverse events incidence	2	638	Risk Ratio (M‐H, Fixed, 95% CI)	1.33 [0.90, 1.98]